CytoSorbents Corp (NAS:CTSO)
$ 0.8 0.0092 (1.16%) Market Cap: 43.45 Mil Enterprise Value: 52.45 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 56/100

Cytosorbents Corp at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 03:30PM GMT
Release Date Price: $3.33 (-2.06%)
Mike Sarcone
Jefferies - Analyst

Final day of the Jefferies New York City 2023 healthcare conference. My name is Mike Sarcone. I'm an analyst on the medical supplies and devices team. And for this session, we have CytoSorbents.

And with us today, we have Dr. Phillip Chan, CEO of CytoSorbents. So Phillip is going to give a presentation. If we have time at the end, we'll do some questions. Phillip, I'll kick it to you.

Phillip Chan
CytoSorbents Corporation - CEO

Great. Thanks, Mike, and thanks, Jefferies, for hosting this conference and for having me as a guest speaker. As a publicly traded company, please let me remind you of our Safe Harbor statement for forward-looking statements.

CytoSorbents is leading the prevention or treatment of life-threatening inflammation and other deadly conditions in the intensive care unit, as well as cardiac surgery using CytoSorb blood purification. At a glance, we are a US-based international medical device company commercializing our EU-approved CytoSorb blood purification technology in 75 countries around

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot